Last reviewed · How we verify

Methylglyoxal Bis(Guanylhydrazone) — Competitive Intelligence Brief

Methylglyoxal Bis(Guanylhydrazone) (MITOGUAZONE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mitoguazone. Area: Oncology.

discontinued mitoguazone Amiloride-sensitive amine oxidase [copper-containing], S-adenosylmethionine decarboxylase proenzyme Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Methylglyoxal Bis(Guanylhydrazone) (MITOGUAZONE). Mitoguazone works by inhibiting the enzyme ribonucleotide reductase, which is involved in DNA synthesis and repair.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Methylglyoxal Bis(Guanylhydrazone) TARGET MITOGUAZONE discontinued mitoguazone Amiloride-sensitive amine oxidase [copper-containing], S-adenosylmethionine decarboxylase proenzyme

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mitoguazone class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methylglyoxal Bis(Guanylhydrazone) — Competitive Intelligence Brief. https://druglandscape.com/ci/mitoguazone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: